From carbohydrate leads to glycomimetic drugs
Identifieur interne : 000E02 ( Main/Exploration ); précédent : 000E01; suivant : 000E03From carbohydrate leads to glycomimetic drugs
Auteurs : Beat Ernst [Suisse] ; John L. Magnani [Suisse]Source :
- Nature Reviews Drug Discovery [ 1474-1776 ] ; 2009-08.
Abstract
Carbohydrates are the most abundant natural products. Besides their role in metabolism and as structural building blocks, they are fundamental constituents of every cell surface, where they are involved in vital cellular recognition processes. Carbohydrates are a relatively untapped source of new drugs and therefore offer exciting new therapeutic opportunities. Advances in the functional understanding of carbohydrate–protein interactions have enabled the development of a new class of small-molecule drugs, known as glycomimetics. These compounds mimic the bioactive function of carbohydrates and address the drawbacks of carbohydrate leads, namely their low activity and insufficient drug-like properties. Here, we examine examples of approved carbohydrate-derived drugs, discuss the potential of carbohydrate-binding proteins as new drug targets (focusing on the lectin families) and consider ways to overcome the challenges of developing this unique class of novel therapeutics.
Url:
DOI: 10.1038/nrd2852
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A16
- to stream Istex, to step Curation: 000913
- to stream Istex, to step Checkpoint: 000136
- to stream Main, to step Merge: 000E04
- to stream Main, to step Curation: 000E02
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">From carbohydrate leads to glycomimetic drugs</title><author><name sortKey="Ernst, Beat" sort="Ernst, Beat" uniqKey="Ernst B" first="Beat" last="Ernst">Beat Ernst</name></author><author><name sortKey="Magnani, John L" sort="Magnani, John L" uniqKey="Magnani J" first="John L." last="Magnani">John L. Magnani</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FA137D5689E91F0105A3EB4CD732314D17053F83</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1038/nrd2852</idno><idno type="url">https://api.istex.fr/ark:/67375/GT4-X5C6FB71-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A16</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A16</idno><idno type="wicri:Area/Istex/Curation">000913</idno><idno type="wicri:Area/Istex/Checkpoint">000136</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000136</idno><idno type="wicri:doubleKey">1474-1776:2009:Ernst B:from:carbohydrate:leads</idno><idno type="wicri:Area/Main/Merge">000E04</idno><idno type="wicri:Area/Main/Curation">000E02</idno><idno type="wicri:Area/Main/Exploration">000E02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">From carbohydrate leads to glycomimetic drugs</title><author><name sortKey="Ernst, Beat" sort="Ernst, Beat" uniqKey="Ernst B" first="Beat" last="Ernst">Beat Ernst</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, CH-4056 Basel</wicri:regionArea><wicri:noRegion>CH-4056 Basel</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Suisse</country></affiliation></author><author><name sortKey="Magnani, John L" sort="Magnani, John L" uniqKey="Magnani J" first="John L." last="Magnani">John L. Magnani</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, CH-4056 Basel</wicri:regionArea><wicri:noRegion>CH-4056 Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Nature Reviews Drug Discovery</title><idno type="ISSN">1474-1776</idno><idno type="eISSN">1474-1784</idno><imprint><publisher>Nature Publishing Group</publisher><date when="2009-08">2009-08</date><biblScope unit="vol">8</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="661">661</biblScope><biblScope unit="page" to="677">677</biblScope><date type="Copyright" when="2009">2009</date></imprint><idno type="ISSN">1474-1776</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1474-1776</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Carbohydrates are the most abundant natural products. Besides their role in metabolism and as structural building blocks, they are fundamental constituents of every cell surface, where they are involved in vital cellular recognition processes. Carbohydrates are a relatively untapped source of new drugs and therefore offer exciting new therapeutic opportunities. Advances in the functional understanding of carbohydrate–protein interactions have enabled the development of a new class of small-molecule drugs, known as glycomimetics. These compounds mimic the bioactive function of carbohydrates and address the drawbacks of carbohydrate leads, namely their low activity and insufficient drug-like properties. Here, we examine examples of approved carbohydrate-derived drugs, discuss the potential of carbohydrate-binding proteins as new drug targets (focusing on the lectin families) and consider ways to overcome the challenges of developing this unique class of novel therapeutics.</div></front></TEI><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Ernst, Beat" sort="Ernst, Beat" uniqKey="Ernst B" first="Beat" last="Ernst">Beat Ernst</name></noRegion><name sortKey="Ernst, Beat" sort="Ernst, Beat" uniqKey="Ernst B" first="Beat" last="Ernst">Beat Ernst</name><name sortKey="Magnani, John L" sort="Magnani, John L" uniqKey="Magnani J" first="John L." last="Magnani">John L. Magnani</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FA137D5689E91F0105A3EB4CD732314D17053F83
|texte= From carbohydrate leads to glycomimetic drugs
}}
| This area was generated with Dilib version V0.6.33. |  |